Moderna, Inc.: Moderna Reports Fourth Quarter and Fiscal Yea

Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29Moderna

Related Keywords

Puerto Rico , Norway , Malaysia , Australia , Taiwan , Japan , United States , Hong Kong , United Kingdom , Madrid , Spain , Canada , Bancel , Rhôalpes , France , Germany , Bangladesh , India , Netherlands , Denmark , Kuwait , Singapore , Belgium , Italy , Sweden , Cambridge , Cambridgeshire , South Korea , Poland , Switzerland , American , Lavina Talukdar , Intratumoral Immuno , Juan Andres , Asia Pacific , Colleen Hussey , Noubar Afeyan , Us Department Of Defense , Research Development , Nasdaq , Development Expenses , Astrazeneca , Moderna Inc , Vertex Pharmaceuticals , Company Recognition , Summary Of Program , Institute For Life Changing Medicines , National Institutes Of Health , World Health Organization , Artificial Intelligence Ai Academy , Drug Administration , Exchange Commission , Vaccine Development , Share Repurchase Program , American Heart Association Scientific Sessions , Melinda Gates Foundation , Ai Academy , Thermo Fisher , National Academy Of Engineering , European Union , Vaccine Research Center , Carnegie Mellon University , Moderna Charitable Foundation , Vaccine Initiative , Corporate Communications , European Medicines Agency , Health Canada , Therapeutic Goods Administration , Chief Executive Officer , Goods Administration , Biologics License Application , Propionic Acidemia , Methylmalonic Acidemia , Program Highlights , Receptor Binding Domain , N Terminal Domain , Fast Track , National Institutes , Research Center , Cell Surface Therapeutics , Regenerative Therapeutics , Astrazeneca Led Phase , American Heart Association , Scientific Sessions , Intracellular Therapeutics , Drug Designation , Najjar Syndrome Type , Crigler Najjar Syndrome Type , Rare Pediatric Disease , Life Changing Medicines , Full Year , Administrative Expenses , Income Taxes , Per Share , Cash Provided , Operating Activities , Purchase Agreements , Effective Tax Rate , Repurchase Program , Charitable Foundation , Manufacturing Partnerships , Artificial Intelligence , Science Careers , Andres Elected , National Academy , Chief Technical Operations , Quality Officer , Moderna Annual Meeting , Analyst Event , Private Securities Litigation Reform Act , Annual Report , Vice President , Infect Dis Now , Moderna , Reports , Fourth , Quarter , Iscal , Ear , 021 , Financial , Results , Rovides , Business , Updates ,